ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer

P Tarantino, G Viale, MF Press, X Hu… - Annals of …, 2023 - Elsevier
Human epidermal growth factor receptor 2 (HER2)-low breast cancer has recently emerged
as a targetable subset of breast tumors, based on the evidence from clinical trials of novel …

The dawn of a new era: targeting the “undruggables” with antibody-based therapeutics

L Qian, X Lin, X Gao, RU Khan, JY Liao, S Du… - Chemical …, 2023 - ACS Publications
The high selectivity and affinity of antibodies toward their antigens have made them a highly
valuable tool in disease therapy, diagnosis, and basic research. A plethora of chemical and …

Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open …

F André, YH Park, SB Kim, T Takano, SA Im, G Borges… - The Lancet, 2023 - thelancet.com
Background In the single-arm, phase 2 DESTINY-Breast01 trial, trastuzumab deruxtecan
showed robust activity in patients with HER2-positive metastatic breast cancer who were …

Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial

F Mosele, E Deluche, A Lusque, L Le Bescond… - Nature medicine, 2023 - nature.com
The mechanisms of action of and resistance to trastuzumab deruxtecan (T-DXd), an anti-
HER2–drug conjugate for breast cancer treatment, remain unclear. The phase 2 DAISY trial …

Recent advances in targeted strategies for triple-negative breast cancer

S Zhu, Y Wu, B Song, M Yi, Y Yan, Q Mei… - Journal of Hematology & …, 2023 - Springer
Triple-negative breast cancer (TNBC), a highly aggressive subtype of breast cancer,
negatively expresses estrogen receptor, progesterone receptor, and the human epidermal …

Optimizing the safety of antibody–drug conjugates for patients with solid tumours

P Tarantino, B Ricciuti, SM Pradhan… - Nature reviews Clinical …, 2023 - nature.com
Over the past 5 years, improvements in the design of antibody–drug conjugates (ADCs)
have enabled major advances that have reshaped the treatment of several advanced-stage …

ADCdb: the database of antibody–drug conjugates

L Shen, X Sun, Z Chen, Y Guo, Z Shen… - Nucleic Acids …, 2024 - academic.oup.com
Antibody-drug conjugates (ADCs) are a class of innovative biopharmaceutical drugs, which,
via their antibody (mAb) component, deliver and release their potent warhead (aka. payload) …

Emerging targeted therapies for HER2-positive breast cancer

MF Mercogliano, S Bruni, FL Mauro, R Schillaci - Cancers, 2023 - mdpi.com
Simple Summary HER2-positive breast cancer (BC), which accounts for~ 20% of BC, is one
of the more aggressive and has the worst overall survival rate among them. These patients …

Exploration of the antibody–drug conjugate clinical landscape

H Maecker, V Jonnalagadda, S Bhakta… - MAbs, 2023 - Taylor & Francis
The antibody–drug conjugate (ADC) field has undergone a renaissance, with substantial
recent developmental investment and subsequent drug approvals over the past 6 years. In …

Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations

A D'Arienzo, A Verrazzo, M Pagliuca… - …, 2023 - thelancet.com
Antibody–drug conjugates (ADCs) represent a novel and evolving class of antineoplastic
agents, constituted by monoclonal antibody linked to biologically active drugs, delivering …